A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

July 28, 2020

Study Completion Date

May 7, 2021

Conditions

Malignant Solid Tumor

Interventions

DRUG

AMC303

AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways

Trial Locations (7)

Jules Bordet Instiut, Brussels

Cliniques Universitaires Saint Luc, Brussels

START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madiedo

Instituto de Investigación Sanitaria INCLIVA, Hospital Clínico de Valencia, Valencia

Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat

Vall d'Hebron Institute of Oncology (VHIO), Barcelona

Hospital Universitario Virgen de la Victoria, Málaga

All Listed Sponsors

lead

amcure GmbH

INDUSTRY

NCT03009214 - A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours | Biotech Hunter | Biotech Hunter